ABVC BioPharma (NASDAQ:ABVC – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for ABVC BioPharma and PainReform, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares ABVC BioPharma and PainReform”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ABVC BioPharma | $510,000.00 | 60.62 | -$7.91 million | ($0.30) | -3.87 |
| PainReform | $20,000.00 | 40.48 | -$5.02 million | ($736.66) | -0.00 |
PainReform has lower revenue, but higher earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ABVC BioPharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Profitability
This table compares ABVC BioPharma and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | N/A | -47.68% | -30.97% |
| PainReform | N/A | N/A | N/A |
Institutional and Insider Ownership
11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
PainReform beats ABVC BioPharma on 7 of the 10 factors compared between the two stocks.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
